Finch Therapeutics Group, Inc., a Somerville, Mass.-based microbiome therapeutics company, closed a $36m Series B financing.
Investors included Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital.
The round brings the total capital raised since launch to $77m.
Led by Mark Smith, Ph.D., CEO, Finch Therapeutics Group is developing novel microbial therapies by using innovative machine-learning algorithms informed by high-throughput molecular data. Through a strategic merger with Crestovo in 2017, the company established a stronger position in addressing the C. difficile epidemic with Crestovo’s lead Full-Spectrum Microbiota™ product, CP101, which is currently being evaluated among patients suffering from recurrent C. difficile infections.
Finch operates a stool donation program and manufactures approximately 1,000 microbial treatments every month. Through its collaboration with OpenBiome, products manufactured by the company are distributed to a network of more than 1,000 providers.
The company has also announced that the U.S. Food and Drug Administration (FDA) has awarded CP101 Fast Track designation. CP101 is an encapsulated, orally-administered Full-Spectrum Microbiota™ product derived from healthy human donors. It is a potentially first-in-class treatment for patients with recurrent C. difficile infections, and is currently being evaluated in Finch’s PRISM 3 study.